UBS Group’s ABVC BioPharma ABVC Stock Holding History

UBS Group’s Portfolio ABVC Stock Details ABVC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$53.9K	Buy	34,123 +32,352	+1,827%	+$40.3K	﹤0.01%	7526
2026 Q1	$1.72K	Sell	1,771 -817	-32%	-$1.35K	﹤0.01%	9457
2025 Q4	$5.51K	Buy	2,588 +739	+40%	+$1.98K	﹤0.01%	8673
2025 Q3	$5.62K	Buy	+1,849	New	+$5.68K	﹤0.01%	8847
2025 Q2	–	Sell	-29,003	Closed	-$30.7K	–	10204
2025 Q1	$30.7K	Buy	29,003 +28,993	+289,930%	+$17.6K	﹤0.01%	7929
2024 Q4	$6	Buy	+10	New	+$6	﹤0.01%	9828
2023 Q1	–	Sell	-428	Closed	-$2.69K	–	9529
2022 Q4	$2.69K	Buy	+428	New	+$3.16K	﹤0.01%	9635
2022 Q2	–	Sell	-127	Closed	-$3K	–	10232
2022 Q1	$3K	Sell	127 -639	-83%	-$17K	﹤0.01%	9415
2021 Q4	$26K	Buy	+766	New	+$24K	﹤0.01%	7529

Other funds holding ABVC

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

UBS Group's ABVC Position: Q2 2026 in Review

UBS Group increased its ABVC BioPharma (ABVC) stake by 1,827% in Q2 2026, buying an estimated $40.3K and bringing the position to 34,123 shares worth $53.9K. The position accounts for ﹤0.01% of the portfolio, ranked #7526.

UBS Group first reported a position in ABVC in Q4 2021 and has held it in 9 quarters since. 15 funds tracked by Wall St. Rank hold ABVC as of Q2 2026.

UBS Group held 34,123 shares of ABVC BioPharma worth $53.9K as of Q2 2026.
UBS Group bought 32,352 ABVC BioPharma shares in Q2 2026, an estimated $40.3K.
ABVC BioPharma made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #7526 holding.
UBS Group first reported a position in ABVC BioPharma in Q4 2021 and has held it in 9 quarters since.
15 funds tracked by Wall St. Rank held ABVC BioPharma as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.